# Cizzle Biotechnology raises £150k to support cancer test rollout

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-raises-150k-to-support-cancer-test-rollout/4121197417
- Published: 2025-05-20T07:24:53+01:00
- Author: Amilia Stone

**Cizzle Biotechnology Holdings Pl**c (LON:CIZ), the UK based diagnostics developer
of early cancer tests, has** **announced that it has raised £150,000 through the
issue of a convertible loan note (the “Note”), to provide additional funding to 
support the Company’s growth strategy, in particular to roll out its CIZ1B early
cancer test in the UK and elsewhere in Europe following the successful licensing
agreement with Cizzle Bio Inc (BIO) in North America.

The Note, which has been subscribed for by Frazer Lang, an existing investor in 
the Company, is convertible at any time, at the election of the Note holder, during
its 24 month term into new ordinary shares in the Company at a price of 1.4 pence
per share. No interest is payable on the Note.

**Background**

The Company’s commercial strategy is to licence globally its proprietary test for
the CIZ1B biomarker for use in the early detection of lung cancer.  Having secured
the Company’s first licence agreement with BIO for North America and the Caribbean,
BIO has already established partnerships with specialist clinical laboratories and
hospitals to enable market penetration and make the test available to as many clinicians
and patients as possible.  The agreement with BIO provides the Company with guaranteed
royalties and up-front fees of US$2.4 million, of which US$400,000 has already been
received, as well as a future equity stake in BIO.  The next payment of US$250,000
is expected at the end of July 2025 as a result of securing BIO’s first hospital
contract in the Caribbean.

The discovery and development of the CIZ1B biomarker test is the result of many 
years of pioneering work by Professor Dawn Coverley, the Company’s founder and CSO,
and her research team at the University of York.  Initially supported by various
UK research grants it has always been the ambition to ensure patients and healthcare
professionals in the NHS and elsewhere should benefit from the Company’s work in
early cancer detection as part of its commercial roll out plans.

The current NHS cancer plan aims to dramatically improve cancer survival by increasing
the proportion of cancers diagnosed at stages 1 and 2 from half to three-quarters
by 2028.  This shift towards earlier diagnosis is expected to save 55,000 additional
lives per year by 2028.  The plan focuses on improving access to diagnosis and treatment,
raising awareness of cancer symptoms, and increasing the number of cancers identified
through screening, including personalised and risk-stratified approaches.

The Company’s focus is to appoint further accredited facilities globally, with the
focus now on the UK and Europe, to launch the commercially scalable CIZ1B biomarker
test to help reduce premature cancer deaths and improve survival rates and quality
of life for cancer patients.

> **Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:**
> _“Following the success of the Company’s licensing strategy in North America, 
> we are now keen to build partnerships in the UK and elsewhere in Europe.  The 
> CIZ1B biomarker and its use in early cancer diagnosis was the result of many years
> of research and development by Professor Coverley, the Founder and CSO of the 
> Company, and her research team at the University of York, and we want to ensure
> this innovation also brings benefit to patients in the UK delivered through the
> NHS and other healthcare providers.  The new funding provided by Frazer Lang, 
> a long standing and supportive shareholder, will now allow us to bring forward
> our plans to make the test available to patients in the UK.”_

> **Commenting, Frazer Lang said:** “_As a dedicated supporter of the Company’s 
> mission to reduce lung cancer’s impact through early detection with a simple, 
> cost-effective blood test, I’m proud to provide additional funding to accelerate
> our efforts to benefit UK patients.  This investment builds on my family’s existing
> stake, increasing our shareholding to 12.87% once the Note is converted.  We are
> wholeheartedly committed to the Company’s success and to saving lives._“

Share on:
